A new white paper from BioNJ, authored by ApexBio President and Founder Shailja Dixit and Center for Medicine in the Public Interest Vice President and Founder Robert Goldberg, outlines a framework by which companies can demonstrate the value of innovative products before market entry.
Goldberg in a statement said the white paper, titled “A Framework for Demonstrating the Value of Medical Innovation,” addresses key gaps in value assessments.
“Current value assessments don’t provide information about which patients will benefit from which new treatments and why,” Goldberg said. “Today’s paradigm frequently assumes one size fits all.”
To read the full press release, click here.